Evaluation of Safety of Thiosonide in Multiple Doses in Patients with Multidrug, Pre-extensively or Extensively Drug-Resistant Pulmonary Tuberculosis: a Multicenter Randomized Controlled Study

The objective: to evaluate safety of Thiosonide in multiple doses, a new domestic anti-tuberculosis drug, in patients with multidrug, pre-extensively or extensively drug-resistant pulmonary tuberculosis.
Subjects and Methods. The safety of Thiosonide was assessed from November 24, 2014 to May 17, 2019 within a multicenter, 12-week, double-blind, randomized, placebo-controlled clinical study (Protocol no. TIO22, Permit no. 661 dated November 24, 2014 by the Russian Ministry of Health). The study included 160 patients aged 18 to 60 years, who were undergoing inpatient or outpatient treatment in 13 clinical centers with the verified diagnosis of MDR TB, pre-XDR TB and XDR TB. Against the background of standard anti-tuberculosis therapy, patients received 200, 400 or 600 mg of Thiosonide or placebo once a day. Treatment duration made 84 days. The following parameters were used to assess safety of the drug: frequency and severity of adverse events (AEs) and serious adverse events (SAEs), number of cases of early discontinuation of the drug due AEs and SAEs, changes in vital signs during a physical examination, abnormal parameters of laboratory and instrumental tests and examinations.
Results. It has been demonstrated that Thiosonide is well-tolerated and safe. During the study, 100 AEs were reported, but only one of them (1%), which was an elevated creatine phosphokinase level, was definitely related to the investigated drug. Statistical analysis reveal no significant relationship between the frequency of AEs and dosage of the drug.
Conclusion. A safety study of Thiosonide, an original anti-tuberculosis drug, in patients with MDR, pre-XDR and XDR pulmonary TB with multiple administration in doses of 200 mg, 400 mg and 600 mg showed its good tolerability, accompanied by single AEs, of which no more than 1% were definitely related to the investigated drug. Due to the above, Thiosonide can be considered as a promising drug for the treatment of MDR/XDR TB patients.

1. Benemanskiy V.V., Yushkov G.G., Bun M.M., Guschin A.S., Zamaschikov S.I. The experimental and clinical characteristic of toxicity of applied anti-tuberculosis drugs (review). Byulleten Vostochno-Sibirskogo NTS SO RАMN, 2011, no. 3-2, pp. 133-139. (In Russ.)

2. Bocharova I.V., Burenkov M.S., Lepekha L.N., Smirnova T.G., Chernousova L.N., Demikhova O.V. Preclinical studies of the specific activity of the new anti-tuberculosis drug of Thiosonide. Tuberculosis and Lung Diseases, 2014, no. 6, pp. 46-50. (In Russ.) https://doi.org/10.21292/2075-1230-2014-0-6-46-50

3. Gayda A.I., Abramchenko A.V., Romanova M.I., Toichkina T.V., Burykhin V.S., Borisov S.E., Filippov A.V., Kuznetsova T.A., Perkhin D.V., Sveshnikova O.M., Lekhlyayder M.V., Panteleev A.M., Toinova S.V., Maslennikova T.I., Galakhova D.O., Populyashina L.N., Saenko G.I., Anisimova E.S., Svicharskaya A.K., Sosova N.A., Lovacheva O.V., Maryandyshev A.O., Samoylova A.G. Justification of chemotherapy duration in patients with multiple and pre-extensive drug resistant tuberculosis in the Russian Federation. Tuberculosis and Lung Diseases, 2022, vol. 100, no. 12, pp. 44-53. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-12-44-53

4. Savchenko A.Yu., Burenkov M.S., Baydin P.S., Ramenskaya G.V., Perova N.V., Kukes V.G. Anti-tuberculosis activity in the presence of drug resistance as a rationale for prospect use of Thiosonide. Siberian Journal of Clinical and Experimental Medicine, 2020, vol. 35, no. 1, pp. 125-132. (In Russ.)

5. Savchenko A.Yu., Ramenskaya G.V., Kukes V.G., Burenkov M.S., Shilov B.V. Comprehensive assessment of the safety of a new antituberculosis drug from the diarylquinolines group. Journal Biomed, 2021, vol. 17, no. 3, pp. 105-110. (In Russ.) https://doi.org/10.33647/2074-5982-17-3-105-110

6. Filinyuk O.V., Felker I.G., Yanova G.V., Buynova L.N., Kolokolova O.V. Risk factors of chemotherapy failure in multiple drug resistant tuberculosis patients. Tuberculosis and Lung Diseases, 2014, no. 1, pp. 20-26. (In Russ.) https://doi.org/10.21292/2075-1230-2014-0-1-20-26

7. Schegertsov D.Yu., Filinyuk O.V., Buynova L.N., Zemlyanaya N.A., Kabanets N.N., Alliluyev A.S. Adverse events during treatment of patients suffering from multiple drug resistant tuberculosis. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 3, pp. 35-43. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-3-35-43

8. Conradie F., Diacon A.H., Ngubane N., Howell P., Everitt D., Crook A.M. Treatment of highly drug-resistant pulmonary tuberculosis. N. Engl. J. Med., 2020, vol. 382, no. 10, pp. 893-902. https://doi.org/10.1056/nejmoa1901814

9. Harris M., Taylor G. Medical statistics made easy. London: Taylor and Francis, 2006.

10. Karmakar M., Rodrigues C.H.M., Holt K.E., Dunstan S.J., Denholm J., Ascher D.B. Empirical ways to identify novel Bedaquiline resistance mutations in AtpE. PLoS One, 2019, vol. 14, no. 5, pp. e0217169. https://doi.org/10.1371/journal.pone.0217169

11. Nunn A.J., Phillips P.P.J., Meredith S.K., Chiang C.Y., Conradie F., Dalai D. A trial of a shorter regimen for rifampin-resistant tuberculosis. N. Engl. J. Med., 2019, no. 380, pp. 1201-1213. https://doi.org/10.1056/nejmoa1811867

12. Peloquin C.A., Davies G.R. The treatment of tuberculosis. Clin. Pharmacol. Ther., 2021, vol. 110, no. 6, pp. 1455-1466. https://doi.org/10.1002/cpt.2261

13. Pontali E., Raviglione M.C., Migliori G.B. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. Eur. Respir. Rev., 2019, vol. 28, no. 152, pp. 190035. https://doi.org/10.1183/16000617.0035-2019

14. Ramachandran G., Swaminathan S. Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf., 2015, vol. 38, no. 3, pp. 253-269. https://doi.org/10.1007/s40264-015-0267-y